Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of Human-Derived Plasma
2.2. Preparation of Anticoagulant Solutions
2.3. Routine and Specialised Coagulation Assays
2.4. Statistical Analysis
3. Results
3.1. Prothrombin Time (PT)
3.2. Activated Partial Thromboplastin Time (APTT)
3.3. Fibrinogen and D-Dimer
3.4. Activated Partial Thromboplastin Time (APTT) Testing May Be Useful for the Measurement of Plasma Levels of Asundexian and Milvexian
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Material | Assays Performed | Catalogue No. | Lot No. | Source |
---|---|---|---|---|
Standard Human Plasma | PT, APTT, Fibrinogen, D-dimer, FXI-OS | 10446238 ORKL17 | 503299 | Siemens Healthineers |
Ci-Trol® 1 | APTT, FXI-OS | 10445601 291070 | 564878 | Siemens Healthineers |
Ci-Trol® 2 | PT, APTT | 10445602 291071 | 548542 | Siemens Healthineers |
Ci-Trol® 3 | PT, APTT | 10445603 291072 | 556574 | Siemens Healthineers |
Control Plasma N | APTT, FXI-OS | 10446234 ORKE41 | 507922 | Siemens Healthineers |
Control Plasma P | Fibrinogen | 10446471 OUPZ17 | 556748 | Siemens Healthineers |
INNOVANCE® Control 2 | D-dimer | 10446005 OPDY03 | 575513 | Siemens Healthineers |
BIOPHEN ™ Plasma Calibrator | APTT, FXI-OS | 22101 | FB06641A | HYPHEN BioMed |
BIOPHEN ™ Normal Control Plasma | APTT, FXI-OS | 223201 | FB06661C | HYPHEN BioMed |
Assay | Reagent | Catalogue No. | Lot No. | Source |
---|---|---|---|---|
PT | Dade® Innovin® Thromborel® S | 10445704 B4212 10484202 OUHP49 | 564635 568155 | Siemens Healthineers |
APTT | Dade® Actin® FS Dade® Actin® FSL Calcium chloride | 10445710 B4218 10445714 B421902 10446232 ORHO37 | 562452 562755 563935 | Siemens Healthineers |
Fibrinogen | Dade® Thrombin Dade® Owren’s Buffer | 10445721 B4233 10445724 B4234 | 567438 569953 | Siemens Healthineers |
D-Dimer | INNOVANCE® D-Dimer | 10445980 OPBP07 | 01214 | Siemens Healthineers |
Factor XIa | Factor XI Deficient Plasma | 10446316 OSDF13 | 503360 | Siemens Healthineers |
References
- Wheelock, K.M.; Ross, J.S.; Murugiah, K.; Lin, Z.; Krumholz, H.M.; Khera, R. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. JAMA Netw. Open 2021, 4, e2137288. [Google Scholar] [CrossRef] [PubMed]
- Iyer, G.S.; Tesfaye, H.; Khan, N.F.; Zakoul, H.; Bykov, K. Trends in the Use of Oral Anticoagulants for Adults with Venous Thromboembolism in the US, 2010–2020. JAMA Netw. Open 2023, 6, e234059. [Google Scholar] [CrossRef] [PubMed]
- Granger, C.B.; Alexander, J.H.; McMurray, J.J.V.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2011, 365, 981–992. [Google Scholar] [CrossRef]
- Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Špinar, J.; et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2013, 369, 2093–2104. [Google Scholar] [CrossRef] [PubMed]
- Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011, 365, 883–891. [Google Scholar] [CrossRef] [PubMed]
- Khan, F.; Tritschler, T.; Kimpton, M.; Wells, P.S.; Kearon, C.; Weitz, J.I.; Büller, H.R.; Raskob, G.E.; Ageno, W.; Couturaud, F.; et al. Long-Term Risk for Major Bleeding during Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Ann. Intern. Med. 2021, 174, 1420–1429. [Google Scholar] [CrossRef]
- Cools, F.; Johnson, D.; Camm, A.J.; Bassand, J.; Verheugt, F.W.A.; Yang, S.; Tsiatis, A.; Fitzmaurice, D.A.; Goldhaber, S.Z.; Kayani, G.; et al. Risks Associated with Discontinuation of Oral Anticoagulation in Newly Diagnosed Patients with Atrial Fibrillation: Results from the GARFIELD-AF Registry. J. Thromb. Haemost. 2021, 19, 2322–2334. [Google Scholar] [CrossRef]
- Hoffman, M.; Monroe, D.M., III. A Cell-based Model of Hemostasis. Thromb. Haemost. 2001, 85, 958–965. [Google Scholar] [CrossRef]
- Berntorp, E.; Fischer, K.; Hart, D.P.; Mancuso, M.E.; Stephensen, D.; Shapiro, A.D.; Blanchette, V. Haemophilia. Nat. Rev. Dis. Primers 2021, 7, 1–19. [Google Scholar] [CrossRef]
- Hsu, C.; Hutt, E.; Bloomfield, D.M.; Gailani, D.; Weitz, J.I. Factor XI Inhibition to Uncouple Thrombosis from Hemostasis. J. Am. Coll. Cardiol. 2021, 78, 625. [Google Scholar] [CrossRef]
- Peyvandi, F.; Palla, R.; Menegatti, M.; Siboni, S.M.; Halimeh, S.; Faeser, B.; Pergantou, H.; Platokouki, H.; Giangrande, P.; Peerlinck, K.; et al. Coagulation Factor Activity and Clinical Bleeding Severity in Rare Bleeding Disorders: Results from the European Network of Rare Bleeding Disorders. J. Thromb. Haemost. 2012, 10, 615–621. [Google Scholar] [CrossRef] [PubMed]
- Barg, A.A.; Livnat, T.; Kenet, G. Factor XI deficiency: Phenotypic Age-Related Considerations and Clinical Approach towards Bleeding Risk Assessment. Blood 2024, 143, 1455–1464. [Google Scholar] [CrossRef] [PubMed]
- Preis, M.; Hirsch, J.; Kotler, A.; Zoabi, A.; Stein, N.; Rennert, G.; Saliba, W. Factor XI Deficiency Is Associated with Lower Risk for Cardiovascular and Venous Thromboembolism Events. Blood 2017, 129, 1210–1215. [Google Scholar] [CrossRef] [PubMed]
- Meijers, J.C.; Tekelenburg, W.L.; Bouma, B.N.; Bertina, R.M.; Rosendaal, F.R. High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. N. Engl. J. Med. 2000, 342, 696–701. [Google Scholar] [CrossRef] [PubMed]
- Sharma, M.; Molina, C.A.; Toyoda, K.; Bereczki, D.; Bangdiwala, S.I.; Kasner, S.E.; Lutsep, H.L.; Tsivgoulis, G.; Ntaios, G.; Czlonkowska, A.; et al. Safety and Efficacy of Factor XIa Inhibition with Milvexian for Secondary Stroke Prevention (AXIOMATIC-SSP): A Phase 2, International, Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Trial. Lancet Neurol. 2024, 23, 46–59. [Google Scholar] [CrossRef]
- Weitz, J.I.; Strony, J.; Ageno, W.; Gailani, D.; Hylek, E.M.; Lassen, M.R.; Mahaffey, K.W.; Notani, R.S.; Roberts, R.; Segers, A.; et al. Milvexian for the Prevention of Venous Thromboembolism. N. Engl. J. Med. 2021, 385, 2161–2172. [Google Scholar] [CrossRef]
- Rao, S.V.; Kirsch, B.; Bhatt, D.L.; Budaj, A.; Coppolecchia, R.; Eikelboom, J.; James, S.K.; Jones, W.S.; Merkely, B.; Keller, L.; et al. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation 2022, 146, 1196–1206. [Google Scholar] [CrossRef]
- Shoamanesh, A.; Mundl, H.; Smith, E.E.; Masjuan, J.; Milanov, I.; Hirano, T.; Agafina, A.; Campbell, B.; Caso, V.; Mas, J.-L.; et al. Factor XIa Inhibition with Asundexian after Acute Non-Cardioembolic Ischaemic Stroke (PACIFIC-Stroke): An International, Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial. Lancet 2022, 400, 997–1007. [Google Scholar] [CrossRef]
- Piccini, J.P.; Caso, V.; Connolly, S.J.; Fox, K.A.A.; Oldgren, J.; Jones, W.S.; Gorog, D.A.; Durdil, V.; Viethen, T.; Neumann, C.; et al. Safety of the Oral Factor XIa Inhibitor Asundexian Compared with Apixaban in Patients with Atrial Fibrillation (PACIFIC-AF): A Multicentre, Randomised, Double-Blind, Double-Dummy, Dose-Finding Phase 2 Study. Lancet 2022, 399, 1383–1390. [Google Scholar] [CrossRef]
- Favaloro, E.J.; Pasalic, L.; Curnow, J.; Lippi, G. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges. Curr. Drug Metab. 2017, 18, 598–608. [Google Scholar] [CrossRef]
- Dunois, C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines 2021, 9, 445. [Google Scholar] [CrossRef]
- Qiao, J.; Tran, M.-H. Challenges to Laboratory Monitoring of Direct Oral Anticoagulants. Clin. Appl. Thromb. 2024, 30, 10760296241241524. [Google Scholar] [CrossRef] [PubMed]
- Lindahl, T.L.; Baghaei, F.; Blixter, I.F.; Gustafsson, K.M.; Stigendal, L.; Sten-Linder, M.; Strandberg, K.; Hillarp, A.; from the Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the Oral, Direct Thrombin Inhibitor Dabigatran on Five Common Coagulation Assays. Thromb. Haemost. 2011, 105, 371–378. [Google Scholar] [CrossRef] [PubMed]
- Hillarp, A.; Gustafsson, K.M.; Faxälv, L.; Strandberg, K.; Baghaei, F.; Fagerberg Blixter, I.; Berndtsson, M.; Lindahl, T.L. Effects of the Oral, Direct Factor Xa Inhibitor Apixaban on Routine Coagulation Assays and Anti-FXa Assays. J. Thromb. Haemost. 2014, 12, 1545–1553. [Google Scholar] [CrossRef] [PubMed]
- Hillarp, A.; Baghaei, F.; Blixter, I.F.; Gustafsson, K.M.; Stigendal, L.; Sten-Linder, M.; Strandberg, K.; Lindahl, T.L. Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Commonly Used Coagulation Assays. J. Thromb. Haemost. 2011, 9, 133–139. [Google Scholar] [CrossRef]
- Hillarp, A.; Strandberg, K.; Baghaei, F.; Fagerberg Blixter, I.; Gustafsson, K.M.; Lindahl, T.L. Effects of the Oral, Direct Factor Xa Inhibitor Edoxaban on Routine Coagulation Assays, Lupus Anticoagulant and Anti-Xa Assays. Scand. J. Clin. Lab. Investig. 2018, 78, 575–583. [Google Scholar] [CrossRef]
- Perera, V.; Wang, Z.; Luettgen, J.; Li, D.; DeSouza, M.; Cerra, M.; Seiffert, D. First-in-Human Study of Milvexian, an Oral, Direct, Small Molecule Factor XIa Inhibitor. Clin. Transl. Sci. 2022, 15, 330–342. [Google Scholar] [CrossRef]
- Kubitza, D.; Heckmann, M.; Distler, J.; Koechel, A.; Schwers, S.; Kanefendt, F. Pharmacokinetics, Pharmacodynamics and Safety of BAY 2433334, a Novel Activated Factor XI Inhibitor, in Healthy Volunteers: A Randomized Phase 1 Multiple-Dose Study. Br. J. Clin. Pharmacol. 2022, 88, 3447–3462. [Google Scholar] [CrossRef]
- Moser, K.A.; Smock, K.J. Direct Oral Anticoagulant (DOAC) Interference in Hemostasis Assays. Hematol. Am. Soc. Hematol. Educ. Program 2021, 2021, 129–133. [Google Scholar] [CrossRef]
- Do, L.; Favaloro, E.; Pasalic, L. An Analysis of the Sensitivity of the Activated Partial Thromboplastin Time (APTT) Assay, as Used in a Large Laboratory Network, to Coagulation Factor Deficiencies. Am. J. Clin. Pathol. 2022, 158, 132–141. [Google Scholar] [CrossRef]
- Favaloro, E.; Kershaw, G.; Mohammed, S.; Lippi, G. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. Semin. Thromb. Hemost. 2019, 45, 022–035. [Google Scholar] [CrossRef]
- Perera, V.; Abelian, G.; Li, D.; Wang, Z.; Zhang, L.; Lubin, S.; Chen, W.; Bello, A.; Murthy, B. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clin. Pharmacokinet. 2022, 61, 857–867. [Google Scholar] [CrossRef] [PubMed]
- Piel, I.; Engelen, A.; Lang, D.; Schulz, S.I.; Gerisch, M.; Brase, C.; Janssen, W.; Fiebig, L.; Heitmeier, S.; Kanefendt, F. Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans. Eur. J. Drug Metab. Pharmacokinet. 2023, 48, 411–425. [Google Scholar] [CrossRef] [PubMed]
- Perera, V.; Wang, Z.; Lubin, S.; Christopher, L.J.; Chen, W.; Xu, S.; Seiffert, D.; DeSouza, M.; Murthy, B. Effects of Rifampin on the Pharmacokinetics and Pharmacodynamics of Milvexian, a Potent, Selective, Oral Small Molecule Factor XIa Inhibitor. Sci. Rep. 2022, 12, 22239. [Google Scholar] [CrossRef]
- Douxfils, J.; Chatelain, C.; Chatelain, B.; Dogné, J.-M.; Mullier, F. Impact of Apixaban on Routine and Specific Coagulation Assays: A Practical Laboratory Guide. Thromb. Haemost. 2013, 110, 283–294. [Google Scholar] [CrossRef]
- Douxfils, J.; Chatelain, B.; Chatelain, C.; Dogné, J.-M.; Mullier, F. Edoxaban: Impact on Routine and Specific Coagulation Assays. A Practical Laboratory Guide. Thromb. Haemost. 2016, 115, 368–381. [Google Scholar] [CrossRef]
- Siriez, R.; Evrard, J.; Dogné, J.-M.; Pochet, L.; Gheldof, D.; Chatelain, B.; Mullier, F.; Douxfils, J. Betrixaban: Impact on Routine and Specific Coagulation Assays—A Practical Laboratory Guide. Thromb. Haemost. 2018, 118, 1203–1214. [Google Scholar] [CrossRef]
- Douxfils, J.; Mullier, F.; Robert, S.; Chatelain, C.; Chatelain, B.; Dogné, J.-M. Impact of Dabigatran on a Large Panel of Routine or Specific Coagulation Assays. Thromb. Haemost. 2012, 107, 985–997. [Google Scholar] [CrossRef]
- Douxfils, J.; Mullier, F.; Loosen, C.; Chatelain, C.; Chatelain, B.; Dogné, J.-M. Assessment of the Impact of Rivaroxaban on Coagulation Assays: Laboratory Recommendations for the Monitoring of Rivaroxaban and Review of the Literature. Thromb. Res. 2012, 130, 956–966. [Google Scholar] [CrossRef]
- Stevenson, K.J.; Easton, A.C.; Curry, A.; Thomson, J.M.; Poller, L. The Reliability of Activated Partial Thromboplastin Time Methods and the Relationship to Lipid Composition and Ultrastructure. Thromb. Haemost. 1986, 55, 250–258. [Google Scholar] [CrossRef]
- Lawrie, A.S.; Kitchen, S.; Purdy, G.; Mackie, I.J.; Preston, F.E.; Machin, S.J. Assessment of Actin FS and Actin FSL Sensitivity to Specific Clotting Factor Deficiencies. Clin. Lab. Haematol. 1998, 20, 179–186. [Google Scholar] [CrossRef] [PubMed]
- Gosselin, R.; Grant, R.P.; Adcock, D.M. Comparison of the Effect of the Anti-Xa Direct Oral Anticoagulants Apixaban, Edoxaban, and Rivaroxaban on Coagulation assays. Int. J. Lab. Hematol. 2016, 38, 505–513. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Buckley, G.T.; Crowley, M.P.; Harte, J.V. Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays. Diagnostics 2024, 14, 1991. https://doi.org/10.3390/diagnostics14171991
Buckley GT, Crowley MP, Harte JV. Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays. Diagnostics. 2024; 14(17):1991. https://doi.org/10.3390/diagnostics14171991
Chicago/Turabian StyleBuckley, Gavin T., Maeve P. Crowley, and James V. Harte. 2024. "Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays" Diagnostics 14, no. 17: 1991. https://doi.org/10.3390/diagnostics14171991